Vaxart Enters $25 Million Stock Purchase Agreement with Lincoln Park Capital
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 17 2026
0mins
Source: seekingalpha
- Stock Purchase Agreement: Vaxart has entered into a share purchase agreement with Lincoln Park Capital Fund to sell up to $25 million of common stock over 24 months, indicating a proactive strategy in capital raising.
- Sales Structure: The sales under this agreement are structured under registration exemptions, subject to SEC effectiveness of a registration statement and other conditions, ensuring compliance and flexibility.
- Sales Control: Vaxart retains full control over the timing and amount of sales, with pricing tied to market levels, which helps mitigate excessive impact on the company's stock price.
- Market Reaction: Despite the agreement's announcement, Vaxart's shares fell by 0.21%, reflecting a cautious market sentiment regarding the transaction.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
